SA518400552B1 - مركبات فوسفوراميدات - Google Patents

مركبات فوسفوراميدات

Info

Publication number
SA518400552B1
SA518400552B1 SA518400552A SA518400552A SA518400552B1 SA 518400552 B1 SA518400552 B1 SA 518400552B1 SA 518400552 A SA518400552 A SA 518400552A SA 518400552 A SA518400552 A SA 518400552A SA 518400552 B1 SA518400552 B1 SA 518400552B1
Authority
SA
Saudi Arabia
Prior art keywords
cladribine
compounds
derivatives
phosphoramidate
phosphoramidate compounds
Prior art date
Application number
SA518400552A
Other languages
English (en)
Inventor
هوج جريفيث
ماجدالينا سلوسارسزيك
ميكالا سيربى
كريستوفير مكجوجان
Original Assignee
نوكانا بلس
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by نوكانا بلس filed Critical نوكانا بلس
Publication of SA518400552B1 publication Critical patent/SA518400552B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

يتعلق هذا الاختراع بمشتقات كلادريبين derivatives of cladribine. تكون المركبات عبارة عن مشتقات فوسفوراميدات phosphoramidate derivatives حيث يكون شق فوسفوراميدات phosphoramidate moiety موضوع على مجموعة 3'-هيدروكسيل 3'-hydroxyl group من كلادريبين. يتعلق الاختراع أيضا بصيغ صيدلانية من مشتقات كلادريبين واستخدامها في طرق علاج. المركبات مفيدة في علاج السرطان treatment of cancer.
SA518400552A 2016-06-01 2018-11-29 مركبات فوسفوراميدات SA518400552B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609601.8A GB201609601D0 (en) 2016-06-01 2016-06-01 Phosphoramidate compounds
PCT/GB2017/051549 WO2017207986A1 (en) 2016-06-01 2017-05-31 Phosphoramidate nucleoside derivatives as anticancer agents

Publications (1)

Publication Number Publication Date
SA518400552B1 true SA518400552B1 (ar) 2021-12-08

Family

ID=56410850

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518400552A SA518400552B1 (ar) 2016-06-01 2018-11-29 مركبات فوسفوراميدات

Country Status (26)

Country Link
US (2) US10906929B2 (ar)
EP (1) EP3464309B1 (ar)
JP (2) JP7025351B2 (ar)
KR (1) KR20190015353A (ar)
CN (1) CN109195981A (ar)
AU (1) AU2017273117B2 (ar)
BR (1) BR112018074961A2 (ar)
CA (1) CA3025440A1 (ar)
CL (1) CL2018003404A1 (ar)
DK (1) DK3464309T3 (ar)
EA (1) EA036409B1 (ar)
ES (1) ES2801448T3 (ar)
GB (1) GB201609601D0 (ar)
HR (1) HRP20200983T1 (ar)
HU (1) HUE051335T2 (ar)
IL (1) IL263121B (ar)
MX (1) MX378839B (ar)
MY (1) MY198880A (ar)
PH (1) PH12018502606A1 (ar)
PL (1) PL3464309T3 (ar)
PT (1) PT3464309T (ar)
SA (1) SA518400552B1 (ar)
SG (1) SG11201810018TA (ar)
SI (1) SI3464309T1 (ar)
WO (1) WO2017207986A1 (ar)
ZA (1) ZA201807652B (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
EA031727B1 (ru) 2014-11-28 2019-02-28 НУКАНА ПиЭлСи Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
RS60600B1 (sr) 2016-05-31 2020-08-31 Kalvista Pharmaceuticals Ltd Derivati pirazola kao inhibitori kalikreina plazme
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
PL3716952T3 (pl) 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
AU2019232478B2 (en) * 2018-03-09 2024-06-06 Medivir Aktiebolag Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
CN110845560B (zh) * 2019-11-21 2021-08-24 广东中科药物研究有限公司 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223939A1 (en) * 2000-07-13 2002-02-05 Micrologix Biotech Inc. Synthesis and antiviral evaluation of nucleic acid based (NAB) libraries
WO2006063149A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
AU2010203416C1 (en) 2009-01-09 2013-07-25 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
SI3447061T1 (sl) 2011-03-01 2022-02-28 NuCana plc Farmacevtska formulacija, ki obsega fosforamidni derivat 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka
US9156872B2 (en) * 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
KR20170005492A (ko) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
US10117888B2 (en) 2014-06-25 2018-11-06 NuCana plc Formulation comprising a gemcitabine-prodrug
EA031727B1 (ru) * 2014-11-28 2019-02-28 НУКАНА ПиЭлСи Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
CN107820494B (zh) 2015-06-09 2020-10-16 艾伯维公司 核受体调节剂
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds

Also Published As

Publication number Publication date
MX2018014859A (es) 2019-03-07
ES2801448T3 (es) 2021-01-11
JP2022051936A (ja) 2022-04-01
HUE051335T2 (hu) 2021-03-01
US20190375779A1 (en) 2019-12-12
EA201892745A1 (ru) 2019-05-31
PL3464309T3 (pl) 2020-10-19
MY198880A (en) 2023-10-02
IL263121B (en) 2021-10-31
CN109195981A (zh) 2019-01-11
PT3464309T (pt) 2020-06-23
SG11201810018TA (en) 2018-12-28
EA036409B1 (ru) 2020-11-06
JP2019517510A (ja) 2019-06-24
DK3464309T3 (da) 2020-06-29
PH12018502606A1 (en) 2019-10-21
EP3464309A1 (en) 2019-04-10
AU2017273117B2 (en) 2021-02-04
SI3464309T1 (sl) 2020-10-30
ZA201807652B (en) 2021-05-26
BR112018074961A2 (pt) 2019-03-12
IL263121A (en) 2018-12-31
EP3464309B1 (en) 2020-06-10
MX378839B (es) 2025-03-11
US10906929B2 (en) 2021-02-02
WO2017207986A1 (en) 2017-12-07
CL2018003404A1 (es) 2019-04-05
CA3025440A1 (en) 2017-12-07
AU2017273117A1 (en) 2018-12-06
GB201609601D0 (en) 2016-07-13
KR20190015353A (ko) 2019-02-13
US20210130387A1 (en) 2021-05-06
HRP20200983T1 (hr) 2020-12-11
JP7025351B2 (ja) 2022-02-24

Similar Documents

Publication Publication Date Title
SA518400552B1 (ar) مركبات فوسفوراميدات
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX2022000789A (es) Compuestos heterociclicos como inmunomoduladores.
MY199220A (en) Heterocyclic compounds as immunomodulators
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
NZ752526A (en) Pyrrolobenzodiazepine conjugates
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
CY1122074T1 (el) Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX386680B (es) Polimorfo de macrociclo de diarilo.
MY193524A (en) Diaryl macrocycles as modulators of protein kinases
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
AU2018380132A8 (en) Tubulin inhibitors
EP3432872A4 (en) COMPOSITIONS AND METHODS FOR USE OF EFLORNITHIN AND DERIVATIVES AND ANALOGUE THEREOF FOR THE TREATMENT OF CANCER, INCLUDING GLIOMEN
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX378607B (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2016005900A (es) Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer.